

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

ICN PHARMACEUTICALS INC  
Form DEFA14A  
May 23, 2002

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant To Section 14(a) Of  
The Securities Exchange Act Of 1934

- Filed by the Registrant  [X]
- Filed by a Party other than the Registrant  [ ]
- Check the appropriate box:
- [ ] Preliminary Proxy Statement
- [ ] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E) (2))
- [ ] Definitive Proxy Statement
- [X] Definitive Additional Materials
- [ ] Soliciting Material Pursuant to Section 240.14a-12

ICN Pharmaceuticals, Inc.

-----  
(Name of Registrant as Specified in its Charter)

N/A

-----  
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)  
Payment of Filing Fee (Check the appropriate box):

- [X] No fee required.
- [ ] Fee computed on table below per Exchange Act Rules 14a-6(i) (4) and 0-11.

(1) Title of each class of securities to which transaction applies:  
-----

(2) Aggregate number of securities to which transaction applies:  
-----

(4) Proposed maximum aggregate value of transaction:  
-----

(5) Total fee paid:  
-----

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a) (2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:  
-----

(2) Form, Schedule or Registration Statement No.:  
-----

(3) Filing Party:  
-----

(4) Date Filed:  
-----

Following is the text of a press release issued by ICN Pharmaceuticals, Inc. on May 22, 2002.

[Letterhead of ICN Pharmaceuticals, Inc.]

Investors:  
-----

Media:  
-----

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

Joe Schepers  
212-754-4422

Mariann Ohanesian  
714-545-0100, ext. 3230

Alan Charles  
714-545-0100, ext. 3013

ICN PHARMACEUTICALS ANNOUNCES ANALYST MEETING  
TO DISCUSS PRO FORMA RESULTS AND 2002 GUIDANCE

COSTA MESA, CA, May 22, 2002 - ICN Pharmaceuticals (NYSE: ICN) today announced that it will host a meeting with analysts and investors to discuss pro forma financial results for its major business units. The company will also discuss its growth strategy for the specialty pharmaceutical business and guidance for 2002. The meeting will be held at the Waldorf Astoria Hotel in New York City on Friday, May 24, 2002 at 11:00 a.m. EDT.

Analysts and investors, as well as other interested parties who cannot attend the meeting in person are invited to participate via conference call and Web cast. The dial-in number to participate live on this call is (719) 457-2684 and the confirmation code is 500581. A replay of the call will be available approximately two hours following the conclusion of the conference call through Tuesday, May 28, 2002, and can be accessed by dialing (719) 457-0820.

The company's presentation materials will be available on ICN's Web site prior to the start of the meeting. To access the Web cast and company materials, go to ICN's corporate Web site at [www.icnpharm.com](http://www.icnpharm.com).

ICN is an innovative, research-based global pharmaceutical company that manufactures, markets and distributes a broad range of prescription and non-prescription pharmaceuticals, and devices under the ICN brand name. Its research and new product development focuses on innovative treatments for dermatology, oncology and hepatology.

Additional information is also available on the Company's Web site at <http://www.icnpharm.com>.

-----

THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. This press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, projections of future sales, operating income, returns on invested assets, regulatory approval processes, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. It also assumes that the Company's operations are not adversely affected by any disruption that may be caused by the pending proxy contest.

###